Abstracts

• Introduction

  Emili Montserrat

  https://doi.org/10.4081/hmr.v1i5.633

  199

  PDF: 143

  • PDF

• Progress and prognosis in chronic lymphocytic leukaemia

  Stephan Stilgenbauer

  https://doi.org/10.4081/hmr.v1i5.634

  187

  PDF: 341

  • PDF

• Fludarabine plus cyclophosphamide combination: a new standard for first-line therapy in chronic lymphocytic leukaemiaa

  Peter Hillmen

  https://doi.org/10.4081/hmr.v1i5.635

  212

  PDF: 416

  • PDF

• Consolidation therapy with alemtuzumab prolongs remission of chronic lymphocytic leukaemia

  Clemens-Martin Wendtner

  https://doi.org/10.4081/hmr.v1i5.636

  231

  PDF: 327

  • PDF

• Combination therapy with alemtuzumab: existing data and future studies

  Robin Foà

  https://doi.org/10.4081/hmr.v1i5.637

  182

  PDF: 219

  • PDF

• The role of alemtuzumab in chronic lymphocytic leukaemia patients with p53 defects

  Andrew R. Pettitt

  https://doi.org/10.4081/hmr.v1i5.638

  214

  PDF: 526

  • PDF

• Advances in the management of follicular lymphoma

  Michele Ghielmini

  https://doi.org/10.4081/hmr.v1i5.639

  195

  PDF: 303

  • PDF

• Radioimmunotherapy in non-Hodgkin’s lymphoma: can it change the course of the disease?

  Timothy Illidge

  https://doi.org/10.4081/hmr.v1i5.640

  300

  PDF: 307

  • PDF

• Where does 90Y-ibritumomab tiuxetan radioimmunotherapy fit? Selecting the right patient

  Martin Bentz

  https://doi.org/10.4081/hmr.v1i5.641

  247

  PDF: 441

  • PDF

• United for success against non-Hodgkin’s lymphoma: role and responsibilities of the nuclear medicine department

  John Buscombe

  https://doi.org/10.4081/hmr.v1i5.642

  182

  PDF: 257

  • PDF

• Diffuse large B-cell lymphoma: the curable disease?

  Michael Pfreundschuh

  https://doi.org/10.4081/hmr.v1i5.643

  373

  PDF: 1484

  • PDF

• New strategies with 90Y-ibritumomab tiuxetan in diffuse large B-cell lymphoma and mantle cell lymphoma

  Franck Morschhauser

  https://doi.org/10.4081/hmr.v1i5.644

  188

  PDF: 347

  • PDF

• An update on90Y-ibritumomab tiuxetan in autologous stem cell transplantation

  Christian Gisselbrecht

  https://doi.org/10.4081/hmr.v1i5.645

  178

  PDF: 338

  • PDF